Free-water Imaging of the Hippocampus is a Sensitive Marker of Alzheimer's Disease

Overview

Journal Neuroimage Clin

Publisher Elsevier

Specialties Neurology
Radiology

Date 2019 Aug 31

PMID 31470214

Citations 26

Authors

Edward Ofori

Steven T DeKosky

Marcelo Febo

Luis Colon-Perez

Paramita Chakrabarty

Ranjan Duara

Malek Adjouadi

Todd E Golde

David E Vaillancourt

Affiliations

Soon will be listed here.

Abstract

Validating sensitive markers of hippocampal degeneration is fundamental for understanding neurodegenerative conditions such as Alzheimer's disease. In this paper, we test the hypothesis that free-water in the hippocampus will be more sensitive to early stages of cognitive decline than hippocampal volume, and that free-water in hippocampus will increase across distinct clinical stages of Alzheimer's disease. We examined two separate cohorts (N = 126; N = 112) of cognitively normal controls, early and late mild cognitive impairment (MCI), and Alzheimer's disease. Demographic, clinical, diffusion-weighted and T1-weighted imaging, and positron emission tomography (PET) imaging were assessed. Results indicated elevated hippocampal free-water in early MCI individuals compared to controls across both cohorts. In contrast, there was no difference in volume of these regions between controls and early MCI. ADNI free-water values in the hippocampus was associated with low CSF AB levels and high global amyloid PET values. Free-water imaging of the hippocampus can serve as an early stage marker for AD and provides a complementary measure of AD neurodegeneration using non-invasive imaging.

Citing Articles

Free-water: A promising structural biomarker for cognitive decline in aging and mild cognitive impairment.

Sathe A, Yang Y, Schilling K, Shashikumar N, Moore E, Dumitrescu L Imaging Neurosci (Camb). 2024; 2:1-16.

PMID: 39512598 PMC: 11540062. DOI: 10.1162/imag_a_00293.

Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction: A Randomized Clinical Trial.

Guttuso Jr T, Zhu J, Wilding G JAMA Netw Open. 2024; 7(10):e2436874.

PMID: 39356507 PMC: 11447566. DOI: 10.1001/jamanetworkopen.2024.36874.

Longitudinal microstructural alterations surrounding subcortical ischemic stroke lesions detected by free-water imaging.

Nagele F, Petersen M, Mayer C, Bonstrup M, Schulz R, Gerloff C Hum Brain Mapp. 2024; 45(8):e26722.

PMID: 38780442 PMC: 11114091. DOI: 10.1002/hbm.26722.

Assessment of Gray Matter Microstructural Alterations in Alzheimer's Disease by Free Water Imaging.

Nakaya M, Sato N, Matsuda H, Maikusa N, Ota M, Shigemoto Y J Alzheimers Dis. 2024; 99(4):1441-1453.

PMID: 38759008 PMC: 11191448. DOI: 10.3233/JAD-231416.

The Association among Hypothalamic Subnits, Gonadotropic and Sex Hormone Plasmas Levels in Alzheimer's Disease.

Ofori E, Solis A, Punjani N, The Alzheimers Disease Neuroimaging Initiative Brain Sci. 2024; 14(3).

PMID: 38539664 PMC: 10968390. DOI: 10.3390/brainsci14030276.

References

Rowe C, Ackerman U, Browne W, Mulligan R, Pike K, OKeefe G . Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008; 7(2):129-35. DOI: 10.1016/S1474-4422(08)70001-2. View

Fellgiebel A, Yakushev I . Diffusion tensor imaging of the hippocampus in MCI and early Alzheimer's disease. J Alzheimers Dis. 2011; 26 Suppl 3:257-62. DOI: 10.3233/JAD-2011-0001. View

Doherty B, Schultz S, Oh J, Koscik R, Dowling N, Barnhart T . Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Alzheimers Dement (Amst). 2015; 1(2):160-169. PMC: 4492165. DOI: 10.1016/j.dadm.2015.01.003. View

Shaw L, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K . Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011; 121(5):597-609. PMC: 3175107. DOI: 10.1007/s00401-011-0808-0. View

Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K . Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011; 38(9):1702-14. DOI: 10.1007/s00259-011-1821-1. View

Verbeek M, Kremer B, Rikkert M, van Domburg P, Skehan M, Greenberg S . Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009; 66(2):245-9. PMC: 3697750. DOI: 10.1002/ana.21694. View

Dale A, Fischl B, Sereno M . Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999; 9(2):179-94. DOI: 10.1006/nimg.1998.0395. View

Jack Jr C, Petersen R, OBrien P, Tangalos E . MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992; 42(1):183-8. DOI: 10.1212/wnl.42.1.183. View

Avants B, Tustison N, Stauffer M, Song G, Wu B, Gee J . The Insight ToolKit image registration framework. Front Neuroinform. 2014; 8:44. PMC: 4009425. DOI: 10.3389/fninf.2014.00044. View

10.

Desikan R, Segonne F, Fischl B, Quinn B, Dickerson B, Blacker D . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006; 31(3):968-80. DOI: 10.1016/j.neuroimage.2006.01.021. View

11.

Kang J, Korecka M, Toledo J, Trojanowski J, Shaw L . Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. Clin Chem. 2013; 59(6):903-16. PMC: 4159709. DOI: 10.1373/clinchem.2013.202937. View

12.

Clerx L, Visser P, Verhey F, Aalten P . New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. J Alzheimers Dis. 2012; 29(2):405-29. DOI: 10.3233/JAD-2011-110797. View

13.

Klein A, Andersson J, Ardekani B, Ashburner J, Avants B, Chiang M . Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage. 2009; 46(3):786-802. PMC: 2747506. DOI: 10.1016/j.neuroimage.2008.12.037. View

14.

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

15.

Aparicio J, Carreno M, Bargallo N, Setoain X, Rubi S, Rumia J . Combined F-FDG-PET and diffusion tensor imaging in mesial temporal lobe epilepsy with hippocampal sclerosis. Neuroimage Clin. 2016; 12:976-989. PMC: 5153605. DOI: 10.1016/j.nicl.2016.05.002. View

16.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

17.

Burciu R, Ofori E, Archer D, Wu S, Pasternak O, McFarland N . Progression marker of Parkinson's disease: a 4-year multi-site imaging study. Brain. 2017; 140(8):2183-2192. PMC: 6057495. DOI: 10.1093/brain/awx146. View

18.

Okonkwo O, Oh J, Koscik R, Jonaitis E, Cleary C, Dowling N . Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. J Int Neuropsychol Soc. 2014; 20(4):422-33. PMC: 4103611. DOI: 10.1017/S1355617714000113. View

19.

Pasternak O, Sochen N, Gur Y, Intrator N, Assaf Y . Free water elimination and mapping from diffusion MRI. Magn Reson Med. 2009; 62(3):717-30. DOI: 10.1002/mrm.22055. View

20.

Mueller S, Weiner M . Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields. Hippocampus. 2009; 19(6):558-64. PMC: 2802542. DOI: 10.1002/hipo.20614. View